Abstract
Seizure is a recognized complication of high-dose busulfan (BU) therapy and phenytoin (DPH) is widely used as prophylaxis. A number of adverse effects have been associated with DPH and it may also interfere with BU metabolism. We used lorazepam (median dose 0.022 mg/kg) i.v. or p.o. before each dose and for 24 h after the last dose of BU as seizure prophylaxis to 29 children undergoing hematopoietic stem cell transplantation. The regimen was well tolerated and drowsiness was the only significant side-effect. Twelve patients were able to receive the entire prophylaxis by mouth. No seizure developed during and within 48 h of BU. Concomitant pharmacokinetic studies showed no alternation of the absorption and clearance of BU during lorazepam administration. Lorazepam can be used as an alternative for seizure prophylaxis during high-dose BU treatment.
MeSH terms
-
Adolescent
-
Adult
-
Anticonvulsants / administration & dosage*
-
Anticonvulsants / adverse effects
-
Antineoplastic Agents, Alkylating / administration & dosage*
-
Antineoplastic Agents, Alkylating / pharmacokinetics
-
Antineoplastic Agents, Alkylating / toxicity
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Busulfan / administration & dosage*
-
Busulfan / pharmacokinetics
-
Busulfan / toxicity
-
Child
-
Child, Preschool
-
Drug Interactions
-
Female
-
Hematologic Neoplasms / complications
-
Hematologic Neoplasms / therapy
-
Hematopoietic Stem Cell Transplantation / adverse effects
-
Hematopoietic Stem Cell Transplantation / methods
-
Humans
-
Infant
-
Lorazepam / administration & dosage*
-
Lorazepam / adverse effects
-
Male
-
Metabolic Clearance Rate
-
Seizures / chemically induced
-
Seizures / prevention & control*
-
Sleep Stages
-
Transplantation Conditioning / adverse effects
-
Transplantation Conditioning / methods
Substances
-
Anticonvulsants
-
Antineoplastic Agents, Alkylating
-
Busulfan
-
Lorazepam